MiR-182-, miR-191, miR-199a-based methods for the diagnosis and prognosis of acute myeloid leukemia (AML)

1. A method of determining survival prognosis in a subject with acute myeloid leukemia (AML), comprising:

obtaining a test sample from subject having, or suspected of having AML, wherein the sample is extracted from at least one of: blood, bone marrow, and tissue suspected of having leukemic cells,

measuring, by hybridization assay, the level of at least one gene product of miR-182 in the test sample,

comparing the level of miR-182 gene product in the test sample relative to a control level of miR-182 gene product in at least one control sample, and

determining the subject's survival prognosis, wherein, if the level of the miR-182 gene product in the test sample is high relative to the level of a corresponding miR-182 gene product in the control sample, the subject is determined to have a shorter overall survival prognosis.

2. The method of claim 1 , which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-20, miR-25, miR-191, miR-199a, and miR-199b and combinations thereof.

3. The method of claim 1 , wherein the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample.

4. The method of claim 1 , wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

5. A method of claim 1 , comprising:

(1) reverse transcribing miR-182 RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;

(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miR-182 miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample; and

(3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,

wherein an increase in the signal of at least one miR-182 miRNA is indicative of the subject either having, or being at risk for developing, shorter overall survival-type AML.

6. A method of determining the prognosis of a subject with acute myeloid leukemia, comprising:

obtaining a test sample from subject having AML, wherein the sample is extracted from at least one of: blood, bone marrow, and tissue suspected of having leukemic cells,

measuring, by hybridization assay, the level of at least one miR-182 gene product in the test sample,

comparing the level of miR-182 gene product in the test sample relative to a control level of miR-182 gene product in at least one control sample, and

determining the subject's prognosis wherein: the miR-182 gene product is associated with an adverse prognosis in AML; and an increase in the level of the at least one miR-182 gene product in the test sample, relative to the level of a corresponding miR-182 gene product in the control sample, is indicative of an adverse prognosis.

7. A method of claim 6 , comprising:

(1) reverse transcribing miR-182 RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;

(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miR-182 miRNA-specific probe oligonucleotides to provide a hybridization profile for said test sample; and

(3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,

wherein an increase in the signal is indicative of the subject either having, or being at risk for developing, AML with an adverse prognosis.

8. A method of determining survival prognosis in a subject with acute myeloid leukemia (AML), comprising:

obtaining a test sample from subject having, or suspected of having AML, wherein the sample is extracted from at least one of: blood, bone marrow, and tissue suspected of having leukemic cells,

measuring, by hybridization assay, the level of at least one miR gene product of miR-191 in the test sample,

comparing the level of miR-191 gene product in the test sample relative to a control level of miR-191 gene product in at least one control sample, and

determining the subject's survival prognosis, wherein, if the level of the miR-191 gene product in the test sample is high relative to the level of a corresponding miR-191 gene product in the control sample, the subject is determined to have a shorter overall survival prognosis.

9. The method of claim 8 , which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-20, miR-25, miR-182, miR-199a, and miR-199b and combinations thereof.

10. The method of claim 8 , wherein the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample.

11. The method of claim 8 , wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

12. A method of claim 8 , comprising:

(1) reverse transcribing miR-191 RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;

(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miR-191 miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample; and

(3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,

wherein an increase in the signal of at least one miR-191 miRNA is indicative of the subject either having, or being at risk for developing, shorter overall survival-type AML.

13. A method of determining the prognosis of a subject with acute myeloid leukemia (AML), comprising:

obtaining a test sample from subject having AML, wherein the sample is extracted from at least one of: blood, bone marrow, and tissue suspected of having leukemic cells,

measuring, by hybridization assay, the level of at least one miR gene product of miR-191 in the test sample,

comparing the level of miR-191 gene product in the test sample relative to a control level of miR-191 gene product in at least one control sample, and

determining the subject's prognosis, wherein the miR-191 gene product is associated with an adverse prognosis in AML; and an increase in the level of the at least one miR-191 gene product in the test sample, relative to the level of a corresponding miR-191 gene product in the control sample, is indicative of an adverse prognosis.

14. A method of claim 13 , further comprising:

(1) reverse transcribing miR-182 RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;

(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miR-182 miRNA-specific probe oligonucleotides to provide a hybridization profile for said test sample; and

(3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,

wherein an increase in the signal is indicative of the subject either having, or being at risk for developing, AML with an adverse prognosis.